Understanding heart disease risks in patients with myelodysplastic syndromes
Official title: Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Run by University of Vermont · NCT06692894 · Data updated 2026-11-12
This study looks at why people with myelodysplastic syndromes are more likely to have heart problems by checking their blood for signs of inflammation over six months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of Vermont Academic / other |
| Locations | 1 site (Burlington, Vermont) |
| Status | Recruiting |
| Started | November 5, 2024 |
| Main results expected | November 2027 |
| Study ends | November 2027 |
| Registry record updated | February 3, 2026 |
| Trial ID | NCT06692894 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of myelodysplastic syndromes.
✕Probably not a fit
Patients who have undergone hematopoietic stem cell transplantation within the last six months or have a diagnosis of MDS with excess blasts 2 will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate why individuals with myelodysplastic syndromes (MDS) are at a higher risk for cardiovascular issues such as heart disease and stroke. Researchers will monitor patients over a period of six months, collecting blood samples to analyze inflammatory markers that may predict heart problems. Participants will provide blood samples during routine visits, allowing researchers to gather data without requiring additional appointments. The goal is to enhance understanding of the relationship between inflammation and cardiovascular health in MDS patients.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for detecting and managing heart disease risks in patients with myelodysplastic syndromes.
How similar studies have gone: While this study focuses on a specific population, similar studies investigating inflammatory markers in cardiovascular disease have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms * Eastern Cooperative Oncology Group (ECOG) performance status ≤3 * Expected survival of at least 6 months * Ability to provide consent Exclusion Criteria: * Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis * Hematopoietic stem cell transplantation expected within 6 months
Where it's running
-
University of Vermont
Burlington, Vermont, United States Recruiting
Study contacts
- Study coordinator: Diego Adrianzen Herrera, MD
- Email: dadrianz@med.uvm.edu
- Phone: (802) 656-2021
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing relapse in high-risk MDS patients after transplantation
This study is testing a new way to help very high-risk patients with myelodysplastic syndromes avoid relapse after a stem cell transplant.
-
Hydroxyurea plus valproic acid or 6‑mercaptopurine plus valproic acid for unfit adults with AML or high‑risk MDS
This study will try two low‑toxicity oral drug combinations—hydroxyurea plus valproic acid, or 6‑mercaptopurine plus valproic acid—in adults with acute myeloid leukemia or high‑risk myelodysplastic syndrome who are not fit for standard chemotherapy.
-
Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome
This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.
-
FXS0683 in relapsed or refractory blood cancers
This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.
-
Brain network changes in adults with anemia measured by fNIRS
This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.
-
Cord blood transplant for children and young adults with blood cancers.
This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.